A Phase 3 Asian Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in Subjects With Hormonal Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer (MBC) Who Have Failed at Least 2 Prior Chemotherapy Regimens
Latest Information Update: 03 Jan 2025
At a glance
- Drugs Sacituzumab govitecan (Primary) ; Capecitabine; Eribulin; Gemcitabine; Vinorelbine
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors Gilead Sciences
Most Recent Events
- 01 Jan 2025 Primary endpoint (Progression-free survival (PFS)) has been met.
- 01 Dec 2024 Results published in the Nature Medicine
- 13 Jun 2024 Planned End Date changed from 1 Mar 2024 to 1 Dec 2025.